source
- FDA approves Roche's Wilserdly for advanced HR-positive, HER2-negative breast cancer with ESR1 mutationThe U.S. Food and Drug Administration has granted approval to Roche's new oral breast cancer therapy, Wilserdly (giredestrant). The decision clears the way for the drug's launch in the United State…
- Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trialHelus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…